PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449A/PTO		Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/662,723
STATEMENT BY APPLICANT	Filing Date	September 15, 2003
( FEB 1 3 2004 )	First Named Inventor	Kim Hwanmook, et al.
1	Group Art Unit	1651
. (use as many sheets (\$ necessary)	Examiner Name	Irene Marx
Sheet 1 Rank 2	Attorney Docket Number	4220-113.1 US

-			U.S. PATENT	DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
Initials *	No.	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Cited Occurrent	Passages or Relevant Figures Appear
m	1	US- 4,266,028	05/05/1981	Nakamura, et al.	
		US-			
_		US-			
		US-	<u> </u>		
		US-			

		FOREIGN PA	TENT DOCU	MENTS		
Examiner	Cita	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	Cite No.1	Country Code <sup>8</sup> - Number <sup>4</sup> - Kind Code <sup>8</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T <sup>0</sup>
				-		

Examiner Signature	Leve n	Date Considered	1/27/06	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01) =

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

nder the Reperwork Reduction oct of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Substitute for form 1449A

	Complete if Known	
Application Number	10/662,723	
Filing Date	September 15, 2003	
First Named Inventor	Kim Hwanmook, et al.	
Group Art Unit	1651	
Examiner Name	Irene Marx	
Attorney Docket Number	4220-113.1 US	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	,
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т2
n	2	DOMINGO GARGALLO-VIOLA, Enzyme Polymorphism, Prodigiosin Production, and Plasmid Fingerprints in Clinical and Naturally Occurring Isolates of Serratia marcescens, Journal of Clinical Microbiology, May 1989, pages 860-868	
	3	N.R. THOMSON, et al., Biosynthesis of carbapenem antibiotic and prodigiosin pigment in Serratia is under quorum sensing control, Molecular Microbiology (2000) 36(3), pages 539-556	
A	4	SANG BAE HAN, et al., T-cell specific immunosuppression by prodigiosin isolated from Serratia marcescens, International Journal of Immunopharmacology 20 (1998), pages 1-13	
			<del> </del> -

Signature   Considered   / / / / /
------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.